Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 7/2003

01-07-2003 | Original Article

Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer

Authors: D. L. Francis, D. Visvikis, D. C. Costa, T. H. A. Arulampalam, C. Townsend, S. K. Luthra, I. Taylor, P. J. Ell

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2003

Login to get access

Abstract

Fluorine-18 labelled fluoro-2-deoxy-d-glucose (18FDG) positron emission tomography (PET) imaging demonstrates the increased glucose consumption of malignant cells, but problems with specificity have led to the development of new PET tracers. [18F]3'-deoxy-3'-fluorothymidine (18FLT) is a new tracer which images cellular proliferation by entering the salvage pathway of DNA synthesis. In this study we compared the cellular uptake of 18FLT and 18FDG in patients with colorectal cancer (CRC). Seventeen patients with 50 primary or metastatic CRC lesions were prospectively recruited. Lesions were initially identified using computed tomography. Patients underwent both 18FDG and 18FLT scanning. Semi-quantitative analysis of tracer uptake was carried out using standardised uptake values. All the primary tumours (n=6) were visualised by both tracers, with 18FDG showing on average twice the uptake of 18FLT. Similar uptake of both tracers was seen in lung and peritoneal lesions, with 18FLT imaging five of the six lung lesions and all of the peritoneal lesions. Of the 32 colorectal liver metastases, 11 (34%) were seen as avid for 18FLT, compared with 31 (97%) for 18FDG. No correlation was seen between the uptake of the two tracers (R 2=0.03). 18FLT shows a high sensitivity in the detection of extrahepatic disease but poor sensitivity for the imaging of colorectal liver metastases, making it unlikely to have a role as a diagnostic tracer in CRC. We have demonstrated that 18FDG and 18FLT image two distinct processes. The prognostic implications of the uptake of 18FLT need to be assessed in terms of response to chemoradiotherapy and survival.
Literature
1.
Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, Birnbaum EH, Fleshman JW, Kodner IJ, Read TE. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000; 43:759–767.PubMed
2.
Kalff V, Hicks RJ, Ware RE, Hogg A, Binns D, McKenzie AF. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2002; 43:492–499.PubMed
3.
Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, Corstens FH, Oyen WJ. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002; 20:388–395.PubMed
4.
Arulampalam TH, Ledermann J, Costa DC. Asymptomatic patient with an increasing concentration of CEA. Lancet Oncol 2001; 2:172.CrossRefPubMed
5.
Libutti SK, Alexander HR Jr, Choyke P, Bartlett DL, Bacharach SL, Whatley M, Jousse F, Eckelman WC, Kranda K, Neumann RD, Carrasquillo JA. A prospective study of 2-[18F] fluoro-2-deoxy-d-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol 2001; 8:779–786.CrossRefPubMed
6.
7.
Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987; 235:1492–1495.PubMed
8.
Hiraki Y, Rosen OM, Birnbaum MJ. Growth factors rapidly induce expression of the glucose transporter gene. J Biol Chem 1988; 263:13655–13662.PubMed
9.
Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, Gambhir SS. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41:1177–1189.PubMed
10.
Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972–1980.PubMed
11.
Bakheet SM, Powe J, Kandil A, Ezzat A, Rostom A, Amartey, J. F-18 FDG uptake in breast infection and inflammation. Clin Nucl Med 2000; 25:100–103.PubMed
12.
Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 1998; 25:259–264.PubMed
13.
Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999; 19:61–77.
14.
Vijayalakshmi D, Belt JA. Sodium-dependent nucleoside transport in mouse intestinal epithelial cells. Two transport systems with differing substrate specificities. J Biol Chem 1988; 263:19419–19423.PubMed
15.
Eary JF, Mankoff DA, Spence AM, Berger MS, Olshen A, Link JM, O'Sullivan F, Krohn KA. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res 1999; 59:615–621.PubMed
16.
Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, Kozawa SM, Zheng M, Lewellen B, Lewellen TK, Grierson JR, Krohn KA. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 1998; 39:1757–1762.PubMed
17.
Grierson, JRand Shields, AF. Radiosynthesis of 3'-deoxy-3'-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 2000; 27:143–156.CrossRefPubMed
18.
Machulla HJ, Blocher A, Kuntzch M, Piert M, Wei R, Grierson JR Simplified labeling approach for synthesing 3'-deoxy-3-[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Chem 2000; 243:843–846.CrossRef
19.
Martin SJ, Eisenbarth JA, Wagner-Utermann U, Mier W, Haberkorn U, Eisenhut M. [18F]FLT: 18F labeling of 3-Boc-1-(2-deoxy-3-0-nosyl-5-0-titryl-b-d-lyxofuranosyl)thymine and other thymine derivatives [abstract]. J Nucl Med 2000; 41:255.
20.
Coloma J, Castell JV. Isozyme pattern of thymidine kinase during liver regeneration. Hoppe Seylers Z Physiol Chem 1984; 365:457–462.PubMed
21.
Nawata H, Kamiya T. Two molecular forms of thymidine kinase in the cytosol of regenerating rat liver. J Biochem (Tokyo) 1975; 78:1215–1224.
22.
Ellims PH, Van Der Weyden MB, Medley G. Thymidine kinase isoenzymes in human malignant lymphoma. Cancer Res 1981; 41:691–695.PubMed
23.
Sakamoto S, Iwama T, Ebuchi M, Tsukada K, Sagara T, Kawasaki T, Murakami S, Kasahara N, Kudo H, Okamoto R. Increased activities of thymidine kinase isozymes in human mammary tumours. Br J Surg 1986; 73:272–273.PubMed
24.
Sasvari-Szekely M, Staub M, Guttmann A, Torcsvari V, Antoni F. Pyrimidine salvage enzymes in human tonsil lymphocytes. I. Separation and properties of thymidine kinase isoenzymes. Acta Biochim Biophys Acad Sci Hung 1985; 20:163–172.PubMed
25.
Munch-Petersen B, Tyrsted G. Induction of thymidine kinases in phytohaemagglutinin-stimulated human lymphocytes. Biochim Biophys Acta 1977; 478:364–375.CrossRefPubMed
26.
Sakamoto S, Iwama T, Tsukada K, Utsunomiya J, Kawasaki T, Okamoto R. Increased activity of thymidine kinase isozyme in human colon tumor. Carcinogenesis 1984; 5:183–185.PubMed
27.
Sakamoto S, Sagara T, Iwama T, Kawasaki T, Okamoto R. Increased activities of thymidine kinase isozymes in human colon polyp and carcinoma. Carcinogenesis 1985; 6:917–919.PubMed
28.
Sakamoto S, Kasahara N, Kudo H, Iwama T. Effects of carcinogenesis on colonic thymidine kinase activity in familial adenomatous polyposis. Carcinogenesis 1992; 13:873–876.PubMed
29.
Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235–238.PubMed
30.
Cleij MC, Steel CJ, Brady F, Ell PJ, Pike VW, Luthra SK. An improved synthesis of 3-deoxy-3-[18F]fluorothymidine. J Lab Comp Radiopharm 2001; 44.
31.
Visvikis D, Francis DL, Costa DC, Mulligan R, Townsend C, Taylor I, Ell PJ. Quantitative comparison of18FDG and 18FLT in colorectal carcinoma [abstract]. Eur J Nucl Med Mol Imaging 2002; 29:S79.
32.
Visvikis D, Costa DC, Croasdale I, Lonn AHR, Bomanji J, Ell PJ. CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET. Eur J Nucl Med Mol Imaging 2003; 30:344–353.PubMed
33.
Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4:1334–1336.CrossRefPubMed
34.
Kubota K. From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001; 15:471–486.
35.
Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993; 34:414–419.PubMed
36.
Buck AC, Schirrmeister HH, Guhlmann CA, Diederichs CG, Shen C, Buchmann I, Kotzerke J, Birk D, Mattfeldt T, Reske SN. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med 2001; 42:721–725.PubMed
37.
Buck AK, Schirrmeister H, Hetzel M, Von Der Heide M, Halter G, Glatting G, Mattfeldt T, Liewald F, Reske SN, Neumaier B. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62:3331–3334.PubMed
38.
Paley MR, Ros PR. Hepatic metastases. Radiol Clin North Am 1998; 36:349–363.PubMed
39.
Slingerland JM, Tannock IF. Cell proliferation and cell death. In: Tannock IF, Hill RP, eds. The basic science of oncology, 3rd edn. New York: McGraw-Hill; 1998:134–165.
Metadata
Title
Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer
Authors
D. L. Francis
D. Visvikis
D. C. Costa
T. H. A. Arulampalam
C. Townsend
S. K. Luthra
I. Taylor
P. J. Ell
Publication date
01-07-2003
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2003
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-003-1187-0

Other articles of this Issue 7/2003

European Journal of Nuclear Medicine and Molecular Imaging 7/2003 Go to the issue

Controversies—For

Is PET the future of Nuclear Medicine?

Original Article

Role of ventilation scintigraphy in diagnosis of acute pulmonary embolism: an evaluation using artificial neural networks

Original Article

99mTc-MIBI scintigraphy for early detection of locally recurrent non-small cell lung cancer treated with definitive radiation therapy

Original Article

Enhanced washout of 99mTc-tetrofosmin in hypertrophic cardiomyopathy: quantitative comparisons with regional 123I-BMIPP uptake and wall thickness determined by MRI

Short Communication

99mTc-HMPAO and 99mTc-ECD perform differently in typically hypoperfused areas in Alzheimer's disease

Molecular Imaging

Specific endothelial binding and tumor uptake of radiolabeled angiostatin